Role of parathyroid hormone-related peptide (PTHrP) in hypercalcemia of malignancy and the development of osteolytic metastases

Journal of Clinical Rheumatology

Volumn 3, Issue 2 SUPPL., 1997, Pages

  De Vernejoul, Marie Christine ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cancer; Hypercalcemia; Metastasis; Parathyroid hormone related peptide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN;

BONE METASTASIS; CANCER; CANCER ADJUVANT THERAPY; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; OSTEOLYSIS; PREVALENCE; PRIORITY JOURNAL;

EID: 0030911595     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199704001-00024     Document Type: Conference Paper

References (36)

1. Vassilopoulo-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993;71:1309-12.
2. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med 1990;112:499-502.
3. Mundy GR. Calcium homeostasis: hypercalcemia and hypocalcemia. 2nd ed. London: M. Dunitz, 1990.
4. Davies M, Hayes ME, Yin AL, Berry JL, Mawer EB. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 1994;78:1202-7.
5. Rosenthal N, Insogna KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab 1985;60:29-33.
6. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991;60:29-33.
7. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978;276:726-8.
8. Bataille R, Alexandre Ch, Chappard D. L'atteinte osseuse myèlomateuse chez l'homme. Rev Rhum Engl Ed 1993;60:261-5.
9. Sato K, Fujii Y, Kasono K, Tsushima T, Shizume K. Production of interleukin-1α and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab 1988;67:592-601.
10. Stromberg K, Hudgins WR, Orth DN. Urinary TGFs in neoplasia: immunoreactive TGF-α in the urine of patients with disseminated breast carcinoma. Biochem Biophys Res Commun 1987;144:1059-68.
11. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893-6.
12. Stewart AF, Broadus AE. Clinical review 16: parathyroid hormone-related proteins - coming of age in the 1990s. J Clin Endocrinol Metab 1990;71:1410-14.
13. Burtis WJ, Brady T, Orloff JJ, Ersbak JB, Warrell RP, Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;332:1106-12.
14. Grill V, Ho P, Body JJ, Lee SC, Kukreja SC, Moseley M, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J CHn Endocrinol Metab 1991;73:1309-15.
15. Audran M, Minebois-Villègas A, Lortholary A, Legrand E, Päscaretti Ch, Giraud Ph, et al. Intérêt du dosage du PTH-rP dans le complement d'exploration des hypercalcèmies. Rev Rhum Engl Ed 1995;62:199-203.
16. Bonjour Ph, Rizzoli R, Hirschel-Scholz S, Caverzasio J. Management of hypercalcemia in relation to pathophysiology. Bone 1987;8:S29-33.
17. Ralston SH, Fogelman I, Gardiner MD, Boyle IT. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcemia in malignancy. BMJ 1984;288:1405-8.
18. Percival RC, Yates AJP, Gray RES, Galloway J, Rogers K, Neal FE, et al. Mechanisms of malignant hypercalcemia in carcinoma of the breast. BMJ 1985;291:776-9.
19. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990;322:605-12.
20. Magro C, Orr FW, Manishen WJ, Sivananthan K, Mokashi SS. Adhesion, chemotaxis, and aggregation of Walker carcinosarcoma cells in response to products of resorbing bone. J Natl Cancer Inst 1985;74:829-38.
21. Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, et al. Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 1988;81:596-600.
22. Thiede MA, Rodan GA. Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science 1988;242:278-80.
23. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone-related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992;28:690-2.
24. Bouizar Z, Spyratos F, Deytieux S, de Vernejoul MC, Jullienne A. PCR analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993;53:5076-8.
25. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544-9.
26. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-7.
27. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
28. Takeichi M. Cadherins in cancer: implications for invasion and metastases. Curr Opin Cell Biol 1993;5:806-11.
29. Mbalaviele G, Chen H, Mundy GR, Yoneda T. The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow. J Clin Invest 1995;95:2757-65.
30. Tondravi M, Quiroz M, Wang M, Teitelbaum SL. Increased rate of skeletal metastases by human breast cancer cells expressing low levels of β3v integrins. J Bone Miner Res 1996;11:S15.
31. Bellahcène A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996;11:665-70.
32. Fritz P, Lemaire V, Tubiana-Hulin M. Intérêt des bisphosphonates dans les ostéopathies malignes. In: deFeze S, Rychewaert A, Aahn MF, Kuntz D, Dryll A, Meyer O, et al, editors. L'actualité rhumatologique. Paris: Expansion Scientifique Française, 1994:340-51.
33. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet 1993;341:1611-3.
34. Body JJ, Dumon JC, Thirion M, Cleeren A. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. J Bone Miner Res 1993;8:701-6.
35. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:495-8.
36. Berenson JR, Lichtenstein A, Porter L, Pimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.